Evidence map›Paper›PMID 34077998›Full record

ArticleImmunity, inflammation and disease2021

Identification and validation of immune-related lncRNA prognostic signatures for melanoma.

Bo Xiao, Liyan Liu, Aoyu Li, Pingxiao Wang, Cheng Xiang, Hui Li, Tao Xiao

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Immunity, inflammation and disease, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Bo XiaoDepartment of Orthopedics, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.ORCID 0000-0003-2328-9997
Liyan LiuDepartment of Orthopedics, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.
Aoyu LiDepartment of Orthopedics, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.
Pingxiao WangDepartment of Orthopedics, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.
Cheng XiangDepartment of Orthopedics, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.
Hui LiDepartment of Orthopedics, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.
Tao XiaoDepartment of Orthopedics, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.
Central South University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionMelanoma is a highly aggressive malignant skin tumor as well as the primary reason for skin cancer-specific deaths. We first identified immune-related long noncoding RNA (lncRNA) prognostic signature and found potential immunotherapeutic targets for melanoma cancer.

methodsRNA-seq data and clinical features of melanoma samples were obtained from The Cancer Genome Atlas. Samples of melanoma were randomly assigned to the training and testing cohort. The immune-related lncRNA signature was then obtained via using univariate, LASSO, and multivariate Cox analysis of patients in the training cohort. Eight significant immune-related lncRNA signature was then subsequently obtained through correlation analysis between immune-related genes and lncRNAs. The association between risk score and immune cell infiltration was finally assessed using TIMER and CIBERSORT.

resultsThree hundred and fifty-six immune-related lncRNAs were obtained. Among them, eight immune-related lncRNAs were identified to build a prognostic risk signature model. The model's performance was then confirmed using the Kaplan-Meier curves, risk plots, and time-dependent receiver-operating characteristic curves in the training cohort. The risk score was identified and confirmed as an independent prognostic factor through univariate and multivariate Cox regression analyses. These results were further verified in the testing and whole cohorts. CIBERSORT algorithm showed that the infiltration levels of T cells CD8, M1 macrophages, plasma cells, T cells CD4 memory activated, T cells gamma delta, and mast cells activated were significantly lower in the high-risk group while the infiltration level of macrophages M0 was significantly lower in the low-risk group.

conclusionThe immune-related lncRNA signature offers prognostic markers and potential immunotherapeutic targets for melanoma.

Indexed as

MelanomaRNA, Long NoncodingBiomarkers, TumorGene Expression Regulation, NeoplasticHumansKaplan-Meier EstimatePrognosisBiomarkers, TumorRNA, Long NoncodingimmunelncRNAsmelanomaprognosisTCGA

Identifiers

PMID34077998
PMCPMC8342236
OpenAlexW3165083504

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.